New research has found that it is possible to cut down the growth of cancer cells at their earliest stages with a new drug.

Research conducted by leading cancer metabolism researchers at Stony Brook University, Paul M. Bingham and Zuzana Zachar, is showing promise in this approach with their clinical investigation of a new class of compounds that disrupt cancer cell mitochondrial metabolism. In collaboration with Cornerstone Pharmaceuticals, Drs. Bingham, Zachar and colleagues at Stony Brook University are evaluating the basic mechanisms of actions behind this class of agents. The relationship with Cornerstone has its roots within Stony Brook’s Center for Biotechnology. Read more here.

The Center for Biotechnology is looking to recruit another BioEntrepreneur-in-Residence (BEIR). BEIRs receive a comprehensive package of incentives to build and lead new bioscience ventures in the Long Island, NY region.

In addition to senior staff support to assist with commercialization strategies, BEIRs will also have access to the resources of Stony Brook University including faculty expertise, core research and engineering facilities, libraries, business incubators, the 245 acre Research Park, and a suite of end-to-end economic development programs. To learn more about the program, click here. Interested entrepreneurs should contact Diane Fabel with a statement of interest and resume, outlining how they would utilize these resources to build a successful bioscience company in the Long Island region. Inquiries will be considered through February 2014, or until appropriate candidates are identified.